Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Tenax Therapeutics (NASDAQ: TENX), a Phase 3 development-stage pharmaceutical company focused on cardiopulmonary therapies, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The conference will be held virtually from April 7-10, 2025. The company's corporate presentation is scheduled for April 7, 2025, at 3:45 p.m. ET. Key participants include Chris Giordano (President & CEO), Dr. Stuart Rich (Chief Medical Officer), and Doug Randall (Chief Business Officer).
Both live and archived versions of the presentation will be available through the company's investor relations webpage.
Tenax Therapeutics (NASDAQ: TENX), un'azienda farmaceutica in fase di sviluppo di terapie cardiopolmonari, ha annunciato la sua partecipazione alla 24ª Conferenza Virtuale Annuale di Needham sulla Salute.
La conferenza si terrà virtualmente dal 7 al 10 aprile 2025. La presentazione aziendale è programmata per 7 aprile 2025, alle 15:45 ET. Tra i partecipanti principali ci sono Chris Giordano (Presidente e CEO), Dr. Stuart Rich (Direttore Medico) e Doug Randall (Direttore Commerciale).
Saranno disponibili sia versioni in diretta che registrate della presentazione tramite la pagina web delle relazioni con gli investitori dell'azienda.
Tenax Therapeutics (NASDAQ: TENX), una empresa farmacéutica en etapa de desarrollo de terapias cardiopulmonares, ha anunciado su participación en la 24ª Conferencia Virtual Anual de Salud de Needham.
La conferencia se llevará a cabo virtualmente del 7 al 10 de abril de 2025. La presentación corporativa está programada para el 7 de abril de 2025, a las 3:45 p.m. ET. Los participantes clave incluyen a Chris Giordano (Presidente y CEO), Dr. Stuart Rich (Director Médico) y Doug Randall (Director Comercial).
Tanto las versiones en vivo como las grabadas de la presentación estarán disponibles a través de la página de relaciones con inversores de la empresa.
테낙스 테라퓨틱스 (NASDAQ: TENX), 심폐 치료에 중점을 둔 3상 개발 단계의 제약 회사가 제24회 니드햄 가상 의료 회의에 참여한다고 발표했습니다.
이 회의는 2025년 4월 7일부터 10일까지 가상으로 개최됩니다. 회사의 기업 발표는 2025년 4월 7일 오후 3시 45분 ET로 예정되어 있습니다. 주요 참가자는 크리스 지오르다노(사장 겸 CEO), 스튜어트 리치 박사(최고 의료 책임자), 더그 랜달(최고 사업 책임자)입니다.
발표의 실시간 및 녹화된 버전은 회사의 투자자 관계 웹페이지를 통해 제공될 예정입니다.
Tenax Therapeutics (NASDAQ: TENX), une entreprise pharmaceutique en phase de développement axée sur les thérapies cardiopulmonaires, a annoncé sa participation à la 24ème Conférence Virtuelle Annuelle de Needham sur la Santé.
La conférence se tiendra virtuellement du 7 au 10 avril 2025. La présentation de l'entreprise est prévue pour le 7 avril 2025 à 15h45 ET. Les principaux participants incluent Chris Giordano (Président et CEO), Dr. Stuart Rich (Directeur Médical) et Doug Randall (Directeur Commercial).
Des versions en direct et enregistrées de la présentation seront disponibles via la page des relations avec les investisseurs de l'entreprise.
Tenax Therapeutics (NASDAQ: TENX), ein pharmazeutisches Unternehmen in der Phase-3-Entwicklung, das sich auf kardiopulmonale Therapien konzentriert, hat seine Teilnahme an der 24. jährlichen virtuellen Needham Gesundheitskonferenz angekündigt.
Die Konferenz findet virtuell vom 7. bis 10. April 2025 statt. Die Unternehmenspräsentation ist für den 7. April 2025 um 15:45 Uhr ET geplant. Zu den Hauptteilnehmern gehören Chris Giordano (Präsident & CEO), Dr. Stuart Rich (Chief Medical Officer) und Doug Randall (Chief Business Officer).
Sowohl Live- als auch aufgezeichnete Versionen der Präsentation werden über die Investor-Relations-Webseite des Unternehmens verfügbar sein.
- None.
- None.
CHAPEL HILL, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the 24th Annual Needham Virtual Healthcare Conference, which is taking place virtually from April 7-10, 2025.
Details of presentation:
Format: Corporate Presentation
Participants: Chris Giordano, President & Chief Executive Officer, Stuart Rich, M.D., Chief Medical Officer, Doug Randall, Chief Business Officer
Date and Time: April 7, 2025, at 3:45 p.m. ET
The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage.
About Tenax Therapeutics
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit www.tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.
Contact:
Investor and Media:
Merrill Barrett
Argot Partners
tenax@argotpartners.com
FAQ
When is Tenax Therapeutics (TENX) presenting at the Needham Healthcare Conference 2025?
Who are the key executives presenting at TENX's Needham Conference presentation?
How can investors access TENX's Needham Conference presentation?
What is the current development stage of Tenax Therapeutics (TENX)?
